Financial and Non-Financial Highlights

The Sumitomo Dainippon Pharma Group has adopted the International Financial Reporting Standards (IFRS) for preparing its consolidated financial statements from the fiscal year ended March 31, 2018.

Revenue, Operating Profit, ROE

The Group expanded the North America business through the acquisition of Sepracor Inc. (currently, Sunovion Pharmaceuticals Inc.) in the U.S. in 2009 and recorded dramatic growth in revenue in fiscal 2010. Subsequently, LATUDA® in North America grew steadily driving consolidated financial results, and the Group achieved all-time high revenue and core operating profit* in fiscal 2017. ROE was 10.2% in fiscal 2018, with a long-term goal of at least 10%.

*R Core operating profit is calculated by deducting from operating profit any gains and losses resulting from non-recurring factors that the Group designates.

R&D Expenses / Ratio to Revenue, Launched Products

Research and development investment is essential for the Group to delivering innovative new pharmaceuticals to patients. We invest proactively with a target R&D expenses ratio of up to 20%. As a result, we launched 10 new drugs between fiscal 2008 and fiscal 2018. Going forward, we will continue to invest proactively in research and development.
In fiscal 2018, the number of employees (consolidated and non-consolidated) decreased due in part to transfers associated with the establishment of DSP Business Partners Co., Ltd. and relocation and transfers of Genomic Science Laboratories associated with the establishment of the Bioscience Research Laboratory at Sumitomo Chemical Co., Ltd.

Our efforts to promote active participation by women, to create an environment that makes it easy for female employees to combine work with family life, and to support career development have been well received by students, and the percentage of women in new graduate recruitment has been increasing annually.

As a result of enhancing our systems and providing an employee-friendly environment, the employee turnover rate due to personal reasons at Sumitomo Dainippon Pharma has been at the 1% level for the past five years.

*1 Non-consolidated
*2 Employee turnover rate due to personal reasons

Note: The CO2 emissions data provided in this section up until last fiscal year is provided on the “Environment” page (page 55).